抗真菌药伊曲康唑的药代动力学研究概况

摘要/Abstract

摘要： 伊曲康唑为三唑类广谱抗真菌药, 对浅表真菌、深部真菌感染均有显著疗效, 且耐受性良好, 临床应用广泛。本文对伊曲康唑在体内的吸收、分布、代谢、排泄的药代动力学特征和影响研究, 以及不同患者群体中的药动学作一综述, 促进临床合理使用。

关键词: 伊曲康唑, 抗真菌药, 药代动力学

Abstract: Itraconazole, a triazole broad-spectrum antifungal drug, is notably effective on superficial and deep fungal infection, and widely used with good tolerance. This article reviews the pharmacokinetic characters, interaction and pharmacokinetics in different patient groups of itraconazole in order to promote its rational application in clinical practice.

Key words: itraconazole, antifugal drug, pharmacokinetics

中图分类号:

R969.1

苗彩云, 陈江飞. 抗真菌药伊曲康唑的药代动力学研究概况[J]. 中国临床药理学与治疗学, 2009, 14(9): 1074-1080.

MIAO Cai-yun, CHEN Jiang-fei. Advance in research for pharmacokinetics on antifugal drug of itraconazole[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1074-1080.

参考文献

[1] Hardin TC, Graybill JR, Fetchick R, et al.Pharmacokinetics of itraconazole following oral administration to normal volunteers[J]. Antimicrob Agents Chemother, 1988, 32(9):1310-1313.
[2] May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers[J]. Pharmacotherapy, 1994, 14(5): 509-513.
[3] Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers[J]. Antimicrob Agents Chemother, 1993, 37(4):778-784.
[4] Lange D, Pavao JH,Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers[J]. J Clin Pharmacol, 1997, 37(6):535-540.
[5] Jaruratanasirikul S, Kleepkaew A.Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole[J]. Eur J Clin Pharmacol, 1997, 52(3):235-237.
[6] Jaruratanasirikul S, Sriwiriy ajan S. Effect of omeprazole on the pharmacolinetics of itraconazole[J]. Eur J Clin Pharmacol, 1998, 54(2):159-161.
[7] Barone JA, MoskovITA BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers[J]. Antimicrob Agents Chemother, 1998, 42(7):1862-1865.
[8] Van de Velde V, Van Peer AP, Heykants JJ, et al.Effect of food on the pharmacokinetics of a new hydroxypropyl-betacyclodextrin formulation of itraconazole[J]. Pharmacotherapy, 1996, 16(3):424-428.
[9] Barone JA, MoskovITA BL, Guarnieri J, et al.Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers[J]. Pharmacotherapy, 1998, 18(2):295-301.
[10] JohnsonMD, Hamilton CD, Drew RH, et al.A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution[J]. J Antimicrob Chemother, 2003, 51(2):453-457.
[11] Kawakami M, Suzuki K, Ishizuka T, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects[J]. Int J Clin Pharmacol Ther, 1998, 36(6):306-308.
[12] Penzak SR, Gubbins PO, Gurley BJ, et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers[J]. Ther Drug Monit, 1999, 21(3): 304-309.
[13] Gubbins PO, McConnell SA, Gurley BJ, et al.Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers[J]. Pharmacotherapy, 2004, 24(4):460-467.
[14] Gubbins PO, Gurley BJ, Williams DK, et al. Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice[J]. Eur J Clin Pharmacol, 2008, 64(3):293-301.
[15] Reynes J, Bazin C, Ajana F, et al.Pharmacokinetics of itraconazole (oral solution)in two groups of human immunodeficiency virus-infected adults with oral candidiasis[J]. Antimicrob Agents Chemother, 1997, 41(11):2554-2558.
[16] Darouiche RO, Setoodeh A, Anaissie EJ.Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography[J]. Antimicrob Agents Chemother, 1995, 39(3):757-759.
[17] Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state[J]. Antimicrob Agents Chemother, 2004, 48(10):3823-3827.
[18] Morimoto K, Tanuma H, Kikuchi I, et al.Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis[J]. My coses, 2004, 47(3/4):104-114.
[19] Seishima M, Oyama z, Oda M, et al.Distribution of an antifungal drug, itraconazole, in pathological and non-pathological tissues[J]. Eur J Dermatol, 2004, 14(1):24-27.
[20] Havu V, Brandt H, Heikkila H, et al.Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison[J]. Br J Dermatol, 1999, 140(1):96-101.
[21] Gupta AK, Groen K, Woestenborghs R, et al.Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis[J]. Clin Exp Dermatol, 1998, 23(3):103-108.
[22] Miyama T, Takanaga H, Matsuo H, et al. P-gly coproteinmediated transport of itraconazole across the blood-brain barrier[J]. Antimicrob Agents Chemother, 1998, 42(7): 1738-1744.
[23] Imbert F, JardinM, Fernandez C, et al. Effect of efflux inhibition on brain uptake of itraconazole in ice infected with Cryptococcus neoformans[J]. Drug Metab Dispos, 2003, 31(3):319-325.
[24] Isoherranen N, Kunze KL, Allen KE, et al.Role of itraconazole metabolites in CYP3A4 inhibition[J]. Drug Metab Dispos, 2004, 32(10):1121-1131.
[25] Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo[J]. Drug Metab Dispos, 2006, 34(4):583-590.
[26] Templeton IE, Thummel KE, Kharasch ED, et al.Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo[J]. Clin Pharmacol Ther, 2008, 83(1):77-85.
[27] Ducharme MP, Slaughter RL,Warbasse LH, et al.Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin[J]. Clin Pharmacol Ther, 1995, 58(6):617-624.
[28] Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients[J]. Eur J Clin Pharmacol, 1998, 54(2):155-158.
[29] Crommentuyn KM, Mulder JW, Sparidans RW, et al. Drugdrug interaction between itraconazole and lopinavir/ ritonavir in an HIV-1-infected patient with disseminated histoplasmosis[J]. Clin Infect Dis, 2004, 38(8):e73-e75.
[30] Koo HL, Hamill RJ, Andrade RA.Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis[J]. Clin Infect Dis, 2007, 45(6):e77-e79.
[31] Jaruratanasirikul S, Sriwirivajan S.Pharmacokinetic study of the interaction between itraconazole and nevirapine[J]. Eur J Clin Pharacol, 2007, 63(5):451-456.
[32] Timmers GJ, Kessels LW,Wilhelm AJ, et al.Effects of cyclosporine on a single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies[J]. Ther Drug Monit, 2008, 30(3):301-305.
[33] Boelaert J, Schurgers M, Matthys E, et al.Itraconazole pharmacokinetics in patients with renal dysfunction[J]. Antimicrob Agents Chemother, 1988, 32(10):1595-1597.
[34] Mohr JF, Finkel KW, Rex JH, et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients[J]. Antimicrob Agents Chemother, 2004, 48(3):3151-3153.
[35] Cavakier A, Leveque D, Peter JD, et al.Pharmacokinetics interaction between itraconazole and ceftriaxone in Yucatan miniature pigs[J]. Antimicrob Agents Chemother, 1997, 41(9):2029-2032.
[36] Cartledge JD, Midgely J, Gazzard BG.Itraconazole solution: higher serum rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis[J]. J Clin Pathol, 1997, 50(6):477-480.
[37] Smith D, Van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients[J]. J Pharm Pharmacol, 1992, 44(7):618-619.
[38] Zhao Q, Zhou H, Pesco-Koplowitz L.Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection[J]. J Clin Pharmacol, 2001, 41(12):1319-1328.
[39] Prentice AG, Warnock DW, Johnson SAN, et al.Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia[J]. J Antimicrob Chemother, 1995, 36(4):657-663.
[40] Michallet M, Persat F, Kranzhofer N, et al.Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation[J]. Bone Marrow Transplant, 1998, 21(12):1239-1243.
[41] Hennig S,Wainwright CE, Bell SC, et al. Population pharmacokinetics of itracoanzole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients[J]. Clin Pharmacokinet, 2006, 45(11):1099-1114.
[42] BoogaertsMA,Maertens J, Van der Geest R, et al.Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy[J]. Antimicrob Agents Chemother, 2001, 45(3): 981-985.
[43] Vandewoude K, Vogelaers D, Decruyenaere J, et al.Concentration in plasma and safety of 7 day of intravenous itraconazole followed by 2 week of oral itraconazole solution in patients in intensive care unit[J]. Antimicrob Agents Chemother, 1997, 41(12):2714-2718.
[44] De Repentigny L, Ratelle J, Leclerc JM, et al. Repeateddose pharmacokinetics of an oral solution of itraconazole in infants and children[J]. Antimicrob Agents Chemother, 1998, 42(2):404-408.
[45] Schmitt C, Perel Y, Harousseau JL, et al.Pharnacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis[J]. Antimcrob Agents Chemother, 2001, 45(5):1561-1564.